A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01260181
Recruitment Status : Completed
First Posted : December 15, 2010
Last Update Posted : February 5, 2018
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 29, 2017
  Actual Study Completion Date : September 29, 2017